Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Astellas Pharma has signed a research pact with Pandion Therapeutics, a start-up in Cambridge, Massachusetts, developing bispecific antibodies for pancreatic autoimmune diseases, particularly type 1 diabetes. Pandion is developing drugs that target specific tissues and simultaneously turn down aberrant immune cell responses that cause autoimmune disease. Astellas will pay Pandion up to $45 million up front and potentially more than $750 million in milestone payments.
This article has been sent to the following recipient: